Lexicon Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LXRX | IVA | SLDB | GPCR | INVA | PHAR | |
|---|---|---|---|---|---|---|
| Market cap | 658.53M | 914.17M | 699.11M | 1.45B | 1.54B | 881.90M |
| P/E (TTM) | — | — | — | — | 5.0 | 38.9 |
| Forward P/E | -7.8 | -5.2 | -3.8 | -9.6 | 9.6 | 69.2 |
| Price/book | 3.8 | 13.8 | 2.9 | 1.1 | 1.4 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +3.50% | −7.42% | +54.69% | −39.17% | +3.30% | −15.24% |
| Today | +1.37% | −3.97% | +3.82% | +0.05% | +1.58% | −3.63% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LXRX news ›Analysts’ Opinions Are Mixed on These Healthcare Stocks: Lexicon Pharmaceuticals (LXRX), Amgen (AMGN) and Demant (OtherWILLF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexicon Pharmaceuticals (LXRX), Amgen (AMGN) and Demant (WILLF). Citi analyst Yigal Nochomovitz maintained a Buy rating on Lexicon Pharmaceuticals yesterday…
Lexicon Pharmaceuticals Q3 2026 Earnings Preview
Preview Lexicon Pharmaceuticals Q3 earnings before market open Nov. - Lexicon Pharmaceuticals (LXRX) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open. - The consensus EPS Estimate is -$0.05 (-25.0%…
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotaglifloz
Piper Sandler Reaffirms Their Buy Rating on Lexicon Pharmaceuticals (LXRX)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Lexicon Pharmaceuticals today and set a price target of $6.00. According to TipRanks, Rahimi is a 5-star analyst with an average return of 23.0% and a 39.26% success rate.…
Analysts’ Top Healthcare Picks: Anixa Biosciences (ANIX), Lexicon Pharmaceuticals (LXRX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Anixa Biosciences (ANIX) and Lexicon Pharmaceuticals (LXRX) with bullish sentiments. In a report released today, Yi Chen from H.C. Wainwright…
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Has Average Target Price of $5.70
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) have been given a consensus recommendation of “Hold” by the five analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has…
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 | March 23, 2026
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near-term milestone payments…
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% – Here’s What Happened
Posted by Defense World Staff on Oct 7th, 2026 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report)’s share price fell 5.2% during trading on Monday. The company traded as low as $1.72 and last traded at $1.7250. Approximately…
Lexicon highlights findings from sotagliflozin studies
Lexicon (LXRX) highlighted findings from two newly reported preclinical studies that provide additional insight into the biological effects of s... Lexicon highlights findings from sotagliflozin studies Lexicon (LXRX) highlighted findings…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- defenseworld.net2
- investors.lexpharma.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.